We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

In this section

Shares

Hikma surges as investors welcome medium-term guidance

Thu 15 May 2025 12:32 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Shares in Hikma Pharmaceuticals surged on Thursday as investors welcomed new medium-term guidance from the company.

Alongside a sell-side analysts and investors even at its manufacturing and R&D facility in Columbus, Ohio, the pharmaceuticals group said that for group revenue, it expects a three-year compound annual growth rate of 6% to 8% between 2024 and 2027.

For operating profit, it expects a three-year compound annual growth rate of 7% to 9%.

In addition, Hikma said introduced a five-year target for group revenue to reach $5bn by 2030.

At 1235 BST, the shares were up 8.1% at 2,098p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast